FY2025 Earnings Estimate for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX) – Investment analysts at Bloom Burton upped their FY2025 EPS estimates for BioSyent in a research report issued on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.81 per share for the year, up from their prior estimate of $0.80. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent’s FY2027 earnings at $0.94 EPS.

BioSyent Stock Performance

CVE:RX opened at C$11.25 on Tuesday. The firm has a 50 day simple moving average of C$11.04 and a 200-day simple moving average of C$11.11. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91. The firm has a market cap of C$128.67 million, a PE ratio of 18.26 and a beta of 0.93. BioSyent has a 1-year low of C$8.24 and a 1-year high of C$12.13.

Insider Activity

In other news, insider FAX Capital Corp. sold 112,400 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Insiders own 33.65% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.